Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

07/05/2014 The new Hewlett-Packard world development center for 3D printers will be in Barcelona 28/04/2014 Loss of memory reversed in Alzheimer's mice models 25/04/2014 More than 30 companies attended the ALBA industry workshop 15/04/2014 European Commission names Barcelona first European Capital of Innovation 11/04/2014 Visit of the Spanish State Secretary for research to the Barcelona Synchrotron Park (BSP) 02/04/2014 High-precision molding in the PTV
41 42 43 44 45 46 47 48 49